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Abstract
Background: Despite plausible biological mechanisms, the differential abilities of phylloquinone (PK) and
menaquinones (MKn) to prevent bone loss remain controversial. The objective of the current study was to
compare the effects of PK, menaquinone-4 (MK-4) and menaquinone-7 (MK-7) on the rate of bone loss in
ovariectomized (OVX) Norway rats. A secondary aim was to compare the effects of vitamin K with those of
bisphosphonates (BP) on bone loss.
Methods: Rats (n = 96) were randomized to 6 dosing groups [n = 16/group; Sham; OVX; OVX + BP (100 μg/kg/
100 μg/mL saline sc); OVX + PK; OVX + MK-4; and OVX + MK-7] for 6 wk. Equimolar daily doses of 107 mg PK/kg,
147 mg MK-4/kg, and 201 mg MK-7/kg diet were provided.
Results: BP significantly increased bone strength and bone mineral density (BMD) vs. OVX (P < 0.05). However, PK,
MK-4 or MK-7 did not change bone strength or BMD compared to the OVX group. Whereas supplementation of
PK, MK-4 and MK-7 increased serum and tibia concentrations of each respective form, PK concentrations were
consistently higher despite equimolar intakes.
Conclusion: PK, MK-4, and MK-7 do not appear to prevent bone loss in OVX rats when administered concurrent
with adequate intake of other nutrients.
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Background
There has been considerable recent interest in the role
of vitamin K in bone metabolism [1-3]. Vitamin K is
essential for the g-carboxylation of specific glutamate
residues in bone-specific proteins, including osteocalcin
(OC). Without this modification, OC lacks the ability to
bind to the mineral hydroxyapatite [4]. In vitro studies
indicate that vitamin K can enhance bone mineralization
and decrease bone resorption, either in its role as an
enzyme cofactor or by mechanisms independent of g-
carboxylation [5,6]. For example, recent evidence sug-
gests that vitamin K promotes the expression of osteo-
blastic markers through steroid and xenobiotic receptors
(SXR)/pregnane X receptor (PXR)-modulated gene tran-
scription [2,6].
Vitamin K exists in two primary forms in the diet:
phylloquinone (PK) and menaquinones (MKn). PK,
menaquinone-4 (MK-4) and menaquinone-7 (MK-7)
have been collectively identified by various investigators
as forms of vitamin K that have a potential role in pre-
venting bone loss [7-10]. PK is the main dietary form of
vitamin K, and is found in green leafy vegetables and
vegetable oils [11]. MKn are primarily synthesized by
bacteria in the gut, and differ from PK in the length of
the side chain, which may contain 2-14 isoprenyl units
at the 3-position of the naphthoquinone ring. MK-7 is
present in traditional Japanese fermented foods (natto).
MK-4 is unique in that it is converted from PK and
menadione [12-15], although the exact mechanisms of
conversion have yet to be elucidated.
Equivocal findings regarding efficacy of vitamin K on
bone may be attributable to use of the different forms of
vitamin K in both human and rodent studies. In Japan,
MK-4 has been used in prevention and treatment of
osteoporosis. Some studies have reported a positive
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effect of menaquinones on bone mineral content [16]
and reduction in fracture risk [17]. However, most stu-
dies failed to show a consistent prevention effect of
menaquinones in osteoporosis [18-20]. Although the
individual effects of PK, MK-4 and MK-7 on bone meta-
bolism has been reported, comparisons among all three
forms have not.
The primary objective of this study was to compare
the effects of three forms of vitamin K on prevention of
bone loss in ovariectomized (OVX) female Norway rats.
The three forms of vitamin K tested were PK, MK-4
and MK-7. Our secondary hypothesis focused on the
comparative effects of different forms of vitamin K with
those of bisphosphonates on bone loss.
Materials and methods
Chemicals
PK, MK-4 and MK-7 were provided by DSM, Eisai and
J-Oil Mills Inc, respectively.
Rats and diets
Rats were maintained and treated under protocols
approved by the Institutional Animal Care and Use
Committee (Bioanalytical Systems, Inc. Evansville).
Ninety six unbred female rats (Rattus norvegicus, 20 wk)
were obtained from Harlan (Indianapolis, IN), and accli-
mated at Bioanalytical Systems, Inc. (Evansville) one day
post surgery prior to dosing. Animals were ranked by
body weight, and maintained individually in stainless
steel suspended wire cages to enable monitoring of food
consumption and to minimize coprophagy. Animals
were randomly assigned into 6 experimental groups (n
= 16/group): Sham group (control animals who surgery
to mimic an ovariectomy, but the ovaries are left intact);
OVX control group; OVX+bisphosphonate (BP) group
[100 μg/mL of saline (100 μg of Fosamax/kg body
weight) daily by subcutaneous injection]; OVX+PK
group (target: 0.3 mmol/kg diet; 135 mg/kg diet); OVX
+MK-4 group (target: 0.3 mmol/kg diet; 133 mg/kg
diet); and OVX+MK-7 group (target: 0.3 mmol/kg diet;
195 mg/kg diet). For 6 wk, all 6 groups were fed a low
vitamin K diet (PK: 0.14 mg/kg diet, Harlan Teklad,
TD.97053) [21] containing 1% calcium and 2.2 IU vita-
min D/g, which were supplemented with one of the
three different forms of vitamin K. Sham group rats
were fed ad libitum. Amount of food offered for all
OVX groups were adjusted weekly based on sham rats
consumption. The food intake was monitored daily, and
body weights were obtained weekly throughout the
experiments.
Fasting blood was collected from all surviving animals
at scheduled euthanasia by carbon dioxide inhalation,
followed by exsanguination. Following processing, serum
was stored at or below -70°C for subsequent analysis.
Femurs, tibia, and lumbar spine (L1-5) were collected
and stored at -20°C.
Serum Ca and PO4 measurements
Ca and PO4 content of serum was determined by induc-
tively coupled plasma optical emission spectrometry
(ICP-OES, Optima 4300 DV, Perkin-Elmer), as described
elsewhere [22].
Bone strength
Right femurs and vertebrae were assessed biomechani-
cally (breaking force and stiffness) and by measures of
bone mineral density (bone calcium content). Bone
strength was analyzed on the basis of a three-point
bending test performed using a TA-ST2 Texture Analy-
zer (Texture Technologies Corp., Scarsdale, NY). To
determine bone calcium content, femurs were dissolved
overnight in 3 mL concentrated HNO3 and diluted to
25 mL using 1 mol/L HCl containing 0.5% La as LaCl3.
From this, an appropriate dilution of each sample was
prepared and the total calcium was assayed using atomic
absorption spectrometry (AAnalyst 300 Perkin-Elmer,
Inc., Norwalk, CT). Amount of calcium per gram of
femur was calculated by dividing the amount of calcium
in the femur by the weight of the femur.
Vitamin K analysis
PK, MK-4 and MK-7 concentrations in the diet, serum
and right tibia were determined by reversed-phase
HPLC, as previous described [23]. The 2’,3’-dihydrovita-
min K was used as an internal standard for all analyses
because of interfering peaks with K(1,25) usually used in
assays.
Statistical analysis
A natural log transformation was applied to serum and
bone measures of PK, MK-4, and MK-7, to reduce
skewness. The characteristics of the OVX and Sham
groups were compared using an independent samples t-
test. One-way ANOVA, followed by Tukey’s Least Sig-
nificant Difference for multiple comparisons, was used
to compare the effect of BP with different forms of vita-
min K on measures of bone strength and the serum and
bone concentrations of vitamin K. All analyses were car-
ried out using SPSS v. 14, and were considered statisti-
cally significant at P < 0.05.
Results
OVX compare to sham
Over the 6 wk study duration, average food intake was
15 g/d for all groups. As expected, all OVX groups had
greater weight gain and lower bone strength compared
to the Sham group (Table 1). OVX did not cause a sig-
nificant alteration in serum or bone vitamin K
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concentrations as compared with that of Sham (data not
shown). None of the rats had clinical signs of bleeding
associated with vitamin K-deficiency.
Bone strength
As shown in Table 2, there was a significant increase in
vertebral breaking force and stiffness in BP compared
with OVX control. However, no effect of any of the vita-
min K-supplemented groups on bone strength was
observed. Bone mineral density (BMD), as assessed by
average femoral calcium, was higher for the BP group
compared with OVX. In contrast, BMD was not
increased in any of the vitamin K-supplemented groups
(Table 2).
Vitamin K concentrations in serum and bone
Changes in serum and bone concentrations of different
forms of vitamin K in response to supplementation are
shown in Table 3. Based on direct HPLC analysis of the
diets, the actual vitamin K contents of the diets were as
follows: PK group (0.23 mmol/kg diet; 107 mg/kg diet);
MK-4 group (0.33 mmol/kg diet; 147 mg/kg diet); and
MK-7 group (0.31 mmol/kg diet; 201 mg/kg diet). At
these doses of PK, MK-4 and MK-7, serum and bone
PK concentrations were significantly greater compared
to other forms of vitamin K. In MK-7 group, there was
the unexpected finding of MK-7 epoxide in serum as
determined by LC/mass spectrometry using an adapta-
tion of the assay described elsewhere (data not shown)
[24]. MK-7 epoxide was not detected in bone. In the
absence of an internal standard for quantification, we
can only acknowledge the presence of MK-7-epoxide in
these samples.
Discussion
Vitamin K fed in one of three forms, PK, MK-4 and
MK-7, for 6 weeks did not prevent bone loss in OVX
Norway rats. These data lend support to the hypothesis
that high doses of vitamin K do not have a preventive
role in bone loss when administered concurrent to ade-
quate amounts of other nutrients, including calcium and
vitamin D.
Vitamin K has been studied in rodent models of
bone loss, primarily in the form of MK-4 [9,25,26].
There is only one other report of a PK supplementa-
tion study in rats. In that study, PK also did not
reduce bone loss following ovariectomy [27]. Although
two studies reported no effect of MK-4 in the absence
of vitamin D [28,29], the majority of studies have
reported a positive effect of MK-4 on bone loss. Doses
of MK-4 studied have ranged from 25 mg/kg diet to
480 mg/kg diet [28,29]. In this study, we used a dose
of 147 mg/kg diet, which falls within this range of
doses reporting positive effects. For comparison, the
current recommended intake of any form of vitamin K
in a rodent diet is 1 mg/kg diet [30]. That others have
reported a positive effect of MK-4 on prevention of
bone loss whereas there were no effects of MK-4
observed in the current study is an unexpected finding
[25,27]. Increased concentrations of MK-4 in serum
and the tibia provide confirmation that MK-4 was
absorbed in this study, albeit with less efficiency than
PK. Similarly, BP expectedly reduced bone loss, provid-
ing further evidence that the study design was suitable
for measuring the effects of different compounds on
prevention of bone loss following ovariectomy in these
Table 1 Body weight, bone biomarkers and
characteristics of OVX control rats and their sham-
operated controls fed low vitamin K diets for 6 wk1,2
Sham OVX
Body weight, g 273.6 ± 3.5 329.6 ± 3.6*
Biochemical Measures
Serum Ca, mg/L 113.1 ± 1.1 114.3 ± 0.8
Serum PO4, mg/L 89.1 ± 2.5 90.9 ± 2.2
Bone Strength
Ultimate Force, N 366.4 ± 24.2 231.8 ± 17.0*
Stiffness, Nmm 225.6 ± 20.4 163.9 ± 20.1*
Femur Ca, mg/g 122.2 ± 3.3 133.3 ± 1.8*
1 Values are means ± SED, n = 16. 2 Low vitamin K diet (Harlan Teklad, TD.
97053, PK: 0.14 mg/kg diet). * Different from Sham, P < 0.05











Body weight, g 329.6 ± 3.6 317.2 ± 4.2 331.9 ± 3.8 330.2 ± 3.9 338.3 ± 4.9
Ultimate Force, N 231.8 ± 17.0a 433.3 ± 21.0c 295.0 ± 15.0ab 245.8 ± 18.8ab 248.4 ± 16.2ab
Stiffness, Nmm 163.9 ± 20.1a 258.8 ± 30.2b 172.8 ± 17.1a 156.1 ± 19.4a 128.9 ± 10.9a
Femur Ca, mg/g 133.3 ± 1.8a 152.2 ± 2.2c 135.2 ± 3.1a 125.7 ± 2.4b 128.0 ± 1.4ab
Serum Ca, mg/L 114.3 ± 0.8a 108.1 ± 0.7b 112.3 ± 1.0a 113.8 ± 0.6a 113.0 ± 0.8a
Serum PO4, mg/L 90.9 ± 2.2a 75.8 ± 1.3b 87.2 ± 2.4a 86.9 ± 1.9a 88.2 ± 2.4a
1 Values are means ± SED, n = 16. 2 Low vitamin K diet (Harlan Teklad, TD. 97053). a,b,c When comparing measures across the five groups, means with different
letter subscripts are statistically different, P < 0.05
Fu et al. Nutrition & Metabolism 2012, 9:12
http://www.nutritionandmetabolism.com/content/9/1/12
Page 3 of 5
rats. Therefore we are currently unable to provide an
explanation for our null findings. However the results
of this rodent study are consistent with recent report
of limited efficacy of MK-4 treatment on reduction of
fraction risk in elderly men and women [20].
More recently, MK-7 has been reported to have
greater efficacy in vitamin K functions compared to
other forms. Of the two animal studies that have evalu-
ated the role of MK-7 on prevention of bone loss fol-
lowing ovariectomy, both have reported beneficial
effects [8,10]. The doses used in previous studies range
from 94 μg/kg diet to 181 mg/kg diet, the latter being
comparable to the 201 mg/kg MK-7 used in the current
study. Moreover, Yamaguchi et al. reported that MK-7
had comparable beneficial effects on bone density when
compared to equimolar doses of MK-4 [10]. In contrast,
a recent clinical trial in children reported no effect of
MK-7 supplementation on bone markers in children
[31]. These conclusions are consistent with the findings
of our rodent study.
An unexpected finding in the current study was the
identification of MK-7 epoxide in the serum of the MK-
7 animals. Vitamin K is recycled in the liver, with the
epoxide form being an intermediate in the vitamin K
cycle. The consistent appearance of the MK-7 epoxide
in the serum suggests that the liver was unable to ade-
quately metabolize the MK-7. The long-term implication
of accumulation of MK-7-epoxide is not known. Unfor-
tunately, we were unable to estimate the concentrations
of MK-7 epoxide because we did not have a suitable
internal standard. However this is an issue that merits
further investigation prior to advocating high doses of
MK-7 intake.
Conclusions
In conclusion, supplementation of PK, MK-4 or MK-7
did not confer a beneficial effect on bone loss in ovar-
iectomized Norway rats fed a diet that meets nutritional
requirements for other nutrients, including calcium and
vitamin D. This would suggest that equivocal findings in
the literature regarding the effect of various forms of
vitamin K on bone cannot be attributed to differences
among the forms studied. These data are also consistent
with a growing number of clinical studies that report no
beneficial effect of vitamin K supplementation on bone
loss in the elderly who are otherwise calcium and vita-
min D-replete [1,18,19].
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